CN Patent

CN101668544B — 经鼻投用制剂

Assigned to Translational Research Ltd · Expires 2013-04-24 · 13y expired

What this patent protects

本发明提供了具有增强的流动性的经鼻应用的制剂。具体地，本发明公开了至少包含由流动性增强组分与生理活性物质构成的复合物的经鼻应用制剂，所述流动性增强组分包含具有特定粉末性质的第一结晶纤维素(A)；具有特定粉末性质的磷酸三钙(B)；和具有特定粉末性质的第二结晶纤维素(C)或具有特定粉末性质的淀粉(D)。

USPTO Abstract

本发明提供了具有增强的流动性的经鼻应用的制剂。具体地，本发明公开了至少包含由流动性增强组分与生理活性物质构成的复合物的经鼻应用制剂，所述流动性增强组分包含具有特定粉末性质的第一结晶纤维素(A)；具有特定粉末性质的磷酸三钙(B)；和具有特定粉末性质的第二结晶纤维素(C)或具有特定粉末性质的淀粉(D)。

Drugs covered by this patent

Patent Metadata

Patent number
CN101668544B
Jurisdiction
CN
Classification
—
Expires
2013-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Translational Research Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.